Molecules / Valsartan

Valsartan API manufacturers

CAS 137862-53-4 Updated 9 July 2026
46
manufacturers with an active filing 31 of them hold a US DMF or a CEP
$160.00
median export price per kg $110.00 to $368.64 · 54 exporters · 2025
321
shortage records on file across 14 countries
1,275
finished-dose makers across 54 regulators
Showing 20 of 46 manufacturers This list is ranked on evidence. Placement cannot be purchased.

Ranked API manufacturers

03

Hetero

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and one valid CEP for valsartan, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.

US DMF
1 active
CEP
1 valid
Last FDA inspection
2025 · NAI
GMP recognised in
23 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
04

Alembic Pharmaceuticals

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and 2 valid CEPs for valsartan, filing since 2010. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.

US DMF
1 active
CEP
2 valid
Last FDA inspection
2025 · VAI
GMP recognised in
18 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
05

Ipca Laboratories

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and 2 valid CEPs for valsartan, filing since 2016. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.

US DMF
1 active
CEP
2 valid
Last FDA inspection
2025 · VAI
GMP recognised in
19 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
06

Harman Finochem

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and one valid CEP for valsartan, filing since 2019. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 3 markets.

US DMF
1 active
CEP
1 valid
Last FDA inspection
2025 · NAI
GMP recognised in
3 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
07

Divi's Laboratories

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and one valid CEP for valsartan, filing since 2011. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.

US DMF
1 active
CEP
1 valid
Last FDA inspection
2025 · NAI
GMP recognised in
2 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
08

MSN Life Sciences

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and one valid CEP for valsartan, filing since 2018. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.

US DMF
1 active
CEP
1 valid
Last FDA inspection
2024 · VAI
GMP recognised in
4 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
09

Zydus Lifesciences

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and one valid CEP for valsartan, filing since 2020. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.

US DMF
1 active
CEP
1 valid
Last FDA inspection
2025 · VAI
GMP recognised in
25 markets
How this listing is sourced EDQM certificate database
FDA, List of Drug Master Files
View profile
10

Cadila Pharmaceuticals

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF for valsartan, filing since 2012. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.

US DMF
1 active
CEP
None on file
Last FDA inspection
2025 · NAI
GMP recognised in
15 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
14

Biocon

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF for valsartan, filing since 2019. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.

US DMF
1 active
CEP
None on file
Last FDA inspection
2025 · VAI
GMP recognised in
29 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
15

Lupin

India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF for valsartan, filing since 2006. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.

US DMF
1 active
CEP
None on file
Last FDA inspection
2025 · VAI
GMP recognised in
30 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
16

Novartis

Switzerland
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF and one valid CEP for valsartan, filing since 2010. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 35 markets.

US DMF
1 active
CEP
1 valid
Last FDA inspection
2024 · VAI
GMP recognised in
35 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
17

Laurus Labs

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 active US DMFs for valsartan, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.

US DMF
2 active
CEP
None on file
Last FDA inspection
2025 · VAI
GMP recognised in
13 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
18

Mankind Pharma

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds 2 active US DMFs for valsartan, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 14 markets.

US DMF
2 active
CEP
None on file
Last FDA inspection
2025 · VAI
GMP recognised in
14 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
19

Synthon

Netherlands
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF for valsartan, filing since 2019. Its GMP is recognised in 14 markets.

US DMF
1 active
CEP
None on file
Last FDA inspection
Not established
GMP recognised in
14 markets
How this listing is sourced FDA, List of Drug Master Files
View profile
20

Biophore India Pharmaceuticals

India
Makes the API
Credentials confirmed against the regulator files on 25 July 2026

Holds one active US DMF for valsartan, filing since 2020. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.

US DMF
1 active
CEP
None on file
Last FDA inspection
2024 · NAI
GMP recognised in
2 markets
How this listing is sourced FDA, List of Drug Master Files
View profile

43 more manufacturers hold filings for valsartan

The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.

Alembic PharmaceuticalsIpca LaboratoriesHarman FinochemDivi's LaboratoriesMSN Life SciencesZydus LifesciencesCadila PharmaceuticalsZhuhai Rundu PharmaceuticalIOL Chemicals and PharmaceuticalsZhejiang Tianyu PharmaceuticalBioconLupinNovartisLaurus LabsMankind PharmaSynthonBiophore India Pharmaceuticals
Open the full list with a free account

Contract manufacturers (13)

Harman Finochem India Granules India India Jubilant Biosys India Divi's Laboratories India Torrent Pharmaceuticals India Corona Remedies India Finecure pharmaceuticals India Titan Laboratories India Next Wave India India Ami Life Sciences India Chemex Global India Jiangsu Zhongbang Pharmaceutical China Polpharma Group Poland

Contract manufacturers make to order rather than holding their own filing for this molecule.

Finished-dose makers (99)

Amneal United States Ohm Laboratories United States Pharmascience Canada ScieGen Pharmaceuticals United States Zentiva, k.s Czech Republic Mepro Pharmaceuticals India Atlantic Pharma - Producoes Farmaceuticas Portugal Torrent Pharmaceuticals India Eurofarma Laboratorios Brazil Abbvie United States Ajanta Pharma India Apotex Canada Teva Israel Sanofi France Mylan Pharmaceuticals United States Sandoz Switzerland ANI Pharmaceuticals United States Rivopharm Switzerland Denk Pharma GmbH Germany Towa Pharmaceutical Europe, S.L Spain

How this list is built

The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.

Active US DMFs
FDA, List of Drug Master Files
Valid CEPs
EDQM certificate database
Inspection outcomes
FDA inspection classifications
GMP certificates
EudraGMDP and national regulators
Price band
Customs export unit values for 2025. These are export values rather than contract prices for regulated-market grade material, which are higher.

Map valsartan for your markets

Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.

Start for free
No sales call.

Also on this molecule

Price history 4 yrs Shortages 321 Recalls 79 Finished dose 99 Contract mfrs 13

By country

India 29

Export price by year

Year Median Exporters
2026 YTD $150.04 18
2025 $160.00 54
2024 $195.00 52
2023 $178.00 56

US dollars per kilogram, customs export unit values.